Lunai Bioworks Inc.

Lunai Bioworks Inc. is an AI-powered biotechnology company focused on accelerating drug discovery, biodefense, and advanced diagnostics. The company's mission is to accelerate pharmaceutical discovery and development through innovative AI-powered platforms, enabling the creation of life-saving treatments faster, more efficiently, and with greater precision. Headquartered in Los Angeles, California, Lunai Bioworks leverages artificial intelligence and living biological systems to decode disease mechanisms and translate insights into clinically relevant therapies.

Lunai Bioworks operates through three segments: RENB, BioSymetrics, and RENC. The company is actively developing genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 for pancreatic tumors and RENB-DC20 for breast cancer. Additionally, it utilizes an artificial intelligence platform technology for early cancer detection and recurrence through a multi-omics approach. The company's offerings extend to AI-powered drug discovery for central nervous system (CNS) diseases and cancer, as well as AI Bio Defense discoveries and tools, with a strategic focus on oncology, neurology, and biosecurity.

In recent developments, Lunai Bioworks Inc. completed an all-stock merger on May 1, 2026, acquiring Neurobridge IP Holdings to obtain a multi-jurisdictional CNS-focused patent portfolio. This transaction was also intended to help the company regain compliance with Nasdaq's stockholders' equity requirements. A special shareholder meeting is scheduled for May 8, 2026, to vote on a reverse stock split, aiming to address Nasdaq's minimum bid price rule. David Weinstein serves as the CEO and Director, appointed in October 2024, with Nathen Fuentes as the CFO since January 2025. The company, formerly known as Renovaro Inc., changed its name to Lunai Bioworks Inc. in August 2025.